{"name":"Arrowhead Pharmaceuticals","slug":"arrowhead","ticker":"ARWR","exchange":"NASDAQ","domain":"arrowheadpharma.com","description":"Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.","hq":"Pasadena, CA","founded":0,"employees":"711","ceo":"Christopher Anzalone","sector":"RNAi Therapeutics / Cardiometabolic","stockPrice":64.25,"stockChange":3.07,"stockChangePercent":5.02,"marketCap":"$9.0B","metrics":{"revenue":16142321,"revenueGrowth":10461.3,"grossMargin":100,"rdSpend":607159000,"netIncome":-1631000,"cash":914710016,"dividendYield":0,"peRatio":40.2,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Redemplo first approved","drug":"Redemplo","drugSlug":"plozasiran","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Atrasentan patent cliff ($1.2B at risk)","drug":"Atrasentan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Redemplo","genericName":"PLOZASIRAN","slug":"plozasiran","indication":"familial chylomicronemia syndrome (FCS)","status":"marketed"}]}],"pipeline":[{"name":"Redemplo","genericName":"PLOZASIRAN","slug":"plozasiran","phase":"marketed","mechanism":"Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides.","indications":["familial chylomicronemia syndrome (FCS)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Arrowhead Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Arrowhead Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $24.6 million and a net loss of $73.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Arrowhead Pharmaceuticals Announces Collaboration with Janssen Pharmaceuticals to Develop RNA Therapies for Cardiovascular Diseases","summary":"Arrowhead Pharmaceuticals announced a collaboration with Janssen Pharmaceuticals to develop RNA therapies for cardiovascular diseases.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"trial","headline":"Arrowhead Pharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of ARO-AAT","summary":"Arrowhead Pharmaceuticals announced positive topline results from a Phase 2 clinical trial of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUGg2VGk3aWxfc1pVMUR1ejJvcUFLa0lDYjVDRllwd2RUalRFVFBYTjNJUXJPMDVQLW91ZmdzR05DR01IQmoxakJOR3E4RER1RThpX2E4U2VRWmFPNGttR3NlODBwaUJPLVkzamtSNUxLQTR5WUV1aGgyQWx0eE9ka1NFNlJEWUdTaER6NE5UUl9IOWp0cHdR?oc=5","date":"2026-03-17","type":"pipeline","source":"Yahoo Finance","summary":"Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Yahoo Finance","headline":"Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQOVRLdTgxcUg3LVJtcElqRjZSZGlFbGpzbU1EMTJRLUI3Nmd2ZExjZTQ0WkVyX19UMzdYZU1QVlgxaVFCQWRMSHI1UGQ2YVVyRm5HYXdENW5YWGpPMVM1SGE0WGs3eUNIbnVBcUVMNy1DRWpyekhwNnlla2F5dzliS1BpSnhMRnUwV2dLdVhsbUVYMFJWQ0E2SVRNOFc?oc=5","date":"2026-02-28","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance","headline":"Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNWTNJSllWRUhBOUdES3RBNkVKdFNaaDJHRkc1QnJoLXdTTGhoTWZvMWVFLU5xbUJpN0F5UWllMWM2b19xUG1oTFhqMnRGclFxLWN0SU0zcVVRSnp4YWtPWS1vTDJsUkpmdUZ6UmxXdGphQnZzd1Q1LXowVm9VOXpGWVJLZ1phWFFVVE1RRVJXT1pSUmdscHhMMDBtRU1RblZDWW4tSWd4NFZkeUdKcHdtdmI1bTQ1cHZ5b2c?oc=5","date":"2026-02-24","type":"pipeline","source":"Stock Titan","summary":"Arrowhead Pharma plans four March healthcare investor events - Stock Titan","headline":"Arrowhead Pharma plans four March healthcare investor events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPR0tZYUVoZE9qZ05jUlExMzdiNVptY0dJZzVCMjZER2JxUXJRY0YtNGJKZ21GNlV5WmhSVGVnSk5GalZlbE9fRTFjNzVFeWtXbDV3aFRLd0hGSzRFVUk2dlFtN0tWUF9NNDhPSVA3SlJDTGhNYm5jWVlLWVY5M1FzOGFQNktTYVoxaFFLWmhpS3VFLUJqRC1sWjk3MkwxSlg5TDVWajkyaVZlLTJQVTQ4RzVjUDU?oc=5","date":"2026-02-05","type":"regulatory","source":"Stock Titan","summary":"Arrowhead wins first FDA drug approval and posts Q1 profit - Stock Titan","headline":"Arrowhead wins first FDA drug approval and posts Q1 profit","sentiment":"positive"},{"date":"2026-02-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUWxYaEZOUjgyZmE1VTRkS2hHaTZwb08yUi1mYXV2U1p6NWt4UWxxMkxtZlFOYkFiZmt0TkpaaW14dy1KbWVzTlE1NXBrSFVZOXc5eE16RlhKdkFBcXg4a240cXZaMXhlNVNiTW1TLVVuMkdNeDZrOFpTY1pVcTUxUTVhQmtWSERyY0VWekVzMGZGa3U0b09nLVNxdk1PYk5rSXNKcUlQV2dOandoV1lHSjJrQUthcVc5?oc=5","date":"2026-01-20","type":"earnings","source":"Stock Titan","summary":"Arrowhead Pharma to reveal fiscal Q1 2026 results in Feb. 5 webcast - Stock Titan","headline":"Arrowhead Pharma to reveal fiscal Q1 2026 results in Feb. 5 webcast","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPdjZ5cW9XY2tVSDhTM2U3TFMxbHVqYnlIVHhUWURXa0pTWVlpbzhScktnOVctU1VTdWxnSlYwb0xvN1VMZHZrclg2NmlQOHpsLXBid01ldkRiSTlHRWl3bFgtbTFEdVBqcklybGdRVjRYaW9fR2ZaWjliTVg5ZDAzb21HWFNBb19NbEdWUXVOTmloblhKU191RjlSLXdBMndjSDlqWjNWNA?oc=5","date":"2026-01-06","type":"pipeline","source":"Investor's Business Daily","summary":"This Biotech Leader Just Doubled Eli Lilly's Weight Loss - Investor's Business Daily","headline":"This Biotech Leader Just Doubled Eli Lilly's Weight Loss - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQNEhUckpnc3lQRTRocjk0UjQtYzFWNVRlWnEyVVY1eVIyRFFZNWJkQ3ZoMG11XzB2YUJCbEJVVVlsR2lsNjlFV3lPT3U2cHFrb3BzeVBlVU1Ca0pGQ1dYTmllV0NTWUxnY1BDOUNBQXdETE9MYXZlSUxyR2NfQVgzNUxNUU5CM0wyejlmLVZabTBhRHJsYmtKZjZBalBlTFNvRXBGdFJ3Qlc3a2gxd1VGRUVIUlV6c3JDZ3Z5Mw?oc=5","date":"2026-01-06","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - Arrowhead Pharmace","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOYlp4Q3ZoSVRKaGdyWWNKSkhNRklKbEJQTmpBLUhJREdQNFhhMVB6N0s5WEFqMUVaZ1hGMi02cjZLM2lYMllwRUNUQTdOaWZuMkhydHp3R004b1diU1pRQU4zVU5wZVZCM1g4TEc2Qkh3SDBacGE0dXVXZzFUd1RHTFVzenJXR1VZSGpCTlowMmw5V2JGTVRIY3BSZEd3cTc0V0UtOEdFclRYbmNfTkF5VXpxM3Y0dnhac0RWc2l2WU52MGF3YkJF?oc=5","date":"2025-11-25","type":"earnings","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Arrowhead Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTnVadEd6V0VHMDQ1dGcySFVnWXRMMHRyMnFfV2FvS3ZoM3pHbzJXNTJ4dG01b0psQ0lUbll2cDA3cHh4X25Lb3BrSmJFMEE2SG5GSXNMYWF1TzZmbzE5aWwzQ0ZXZzVZejlFTmxHNUQ0NWJzcm9xa1hNVEwxemVHZ2xYV2N2RUIwZjNIYWJ0YkpBNG5kMUN0RjdobEFBcHVUQlhVUWR6cGVkUUx2NTJ5eEdFZnRPYzkwN0h4UzdRQjBUVERvZ2c?oc=5","date":"2025-11-24","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSWVLdWFYdnNJTEt3enUxeUZVZFJIQndzd3J1VGxxR3MzSHY2UXVsMkVnN2pkVmVhOWJHSnB4UmJ0Qjc5QVBHX25wa0UzQ3RqNHZodnVSclB1aGdzeXNhLXJaY3FtN0VWOHBfU0lGZlpvNmExQTE5OW4zc3hfWHdiSWQzVmU5VzI4TkNaOWtlTHhpdHlhQVBvc256b0xuTTMyVUkxUVVWbndQMGYwRDhLUl9iOTZ0di1yT1AzSVVmYVNxQQ?oc=5","date":"2025-11-18","type":"regulatory","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Famili","sentiment":"positive"}],"patents":[{"drugName":"Atrasentan","drugSlug":"atrasentan","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Alnylam Pharmaceuticals","Regeneron Pharmaceuticals"],"therapeuticFocus":["Cardiometabolic","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":16142321,"revenuePeriod":"2018-09-30","revenueHistory":[{"value":16142321,"period":"2018-09-30"},{"value":11255000,"period":"2018-09-30"},{"value":727375,"period":"2018-06-30"},{"value":650125,"period":"2018-03-31"},{"value":3509821,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":607159000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1631000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1385295000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":64.25,"previousClose":61.18,"fiftyTwoWeekHigh":76.76,"fiftyTwoWeekLow":9.63,"fiftyTwoWeekRange":"9.635 - 76.76","fiftyDayAverage":62.37,"twoHundredDayAverage":43.58,"beta":1.27,"enterpriseValue":8344897536,"forwardPE":-15,"priceToBook":15.53,"priceToSales":8.25,"enterpriseToRevenue":7.65,"enterpriseToEbitda":25.62,"pegRatio":0,"ebitda":325649984,"ebitdaMargin":29.8,"freeCashflow":170725872,"operatingCashflow":339304992,"totalDebt":698163008,"debtToEquity":124.1,"currentRatio":3.38,"returnOnAssets":14.4,"returnOnEquity":75.5,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":81.09,"targetHighPrice":110,"targetLowPrice":35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.8,"institutionHeldPercent":84.6,"sharesOutstanding":140032190,"floatShares":122039454,"sharesShort":11428679,"shortRatio":5.1,"shortPercentOfFloat":8.2,"epsTrailing":1.6,"epsForward":-4.3,"revenuePerShare":7.97,"bookValue":4.14,"officers":[{"age":56,"name":"Dr. Christopher R. Anzalone Ph.D.","title":"Chairman, CEO & President"},{"age":59,"name":"Mr. Daniel J. Apel","title":"Chief Financial Officer"},{"age":61,"name":"Mr. Patrick  O'Brien J.D., PharmD","title":"COO & Secretary"},{"age":46,"name":"Dr. James C. Hamilton M.D., MBA","title":"Chief Medical Officer and Head of R&D"},{"age":null,"name":"Dr. Mark M. Davis Ph.D.","title":"Founder and Founder & Director of Insert Therapeutics Inc & Calando"},{"age":null,"name":"Dr. Tao  Pei Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. Vincent  Anzalone CFA","title":"Head of Investor Relations & VP"},{"age":null,"name":"Mr. Howard  Lovy","title":"Director of Communications"}],"industry":"Biotechnology","irWebsite":"http://www.arrowheadresearch.com/invest.html","website":"https://arrowheadpharma.com","phone":"626 304 3400"}}